Chinese biopharma firm Adlai Nortye nets $100m in Series C round - (DealStreetAsia via NewsPoints Desk)

  • Adlai Nortye, a China-based biopharmaceutical firm developing immune-oncology medicines, announced the completion of nearly $100 million in a Series C round of financing, reported DealStreetAsia.

  • According to the news source, the company has several drug candidates ranging from early pre-clinical to the Phase III-ready stage.

  • Adlai Nortye's three major clinical stage products are AN0025, AN2025 (buparlisib), and AN1004 (pelareorep).

To read more NewsPoints articles, click here.